SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2

SciBase completed a rights issue 96.4% subscribed (61.3% via rights, 35.1% without) at SEK 0.20 per share, raising approximately SEK 79.9 million before transaction costs (~SEK 3.4m). The board also executed a directed set-off issue of 209,075,476 shares at the same SEK 0.20 price to settle receivables from a TO 2 warrant repurchase offer; together the issues increase the share count by 608,347,357 to 1,022,530,000 shares, diluting existing holders by ~59.5%. Trading in the new shares is expected around 19 Feb 2026; advisors and certified adviser named. The transaction secures near-term financing but imposes significant dilution, a key consideration for investors' positioning.

Analysis

Market structure: The combined Rights Issue and Set-off Issue dilutes existing holders by ~59.5% and injects ~79.9 MSEK (net ~76.5 MSEK after costs), creating immediate share overhang and likely putting downward pressure on SciBase (SciBase Holding AB) share price into trading resumption (~19 Feb 2026). Winners are cash-needy company lenders/contributing warrant holders who converted receivables into equity; losers are existing minority shareholders and short-term liquidity providers because float increases by +147% (414M -> 1,022M shares). Cross-asset impact is muted: SEK may see negligible pressure; options/vol will jump for the single-stock due to thin liquidity, while broader medtech ETFs (IHI, XLV) see no direct move but could attract rotation flows from small-cap risk sellers.

Risk assessment: Tail risks include regulatory clinical setbacks, an ISP FDI Act block for large outside investors, or failure to convert proceeds into revenue-generating milestones—each could wipe out value in quarters. Near-term (days-weeks): pricing pressure and elevated volatility; short-term (1-3 months): market digestion of new float and any follow-on financing; long-term (≥12 months): depends on commercial adoption of Nevisense and cash runway (estimate: recent raise extends runway ~12–18 months at current burn if spending steady). Hidden dependency: remaining TO2 warrants (≈80.4M) and potential further financings; catalysts are trading of new shares (~19 Feb), any clinical/regulatory announcements, and insider/anchor investor activity.

Trade implications: Direct short on SciBase at re-list (target mean-reversion to subscription price SEK 0.20) is pragmatic: consider small short sizes (0.5–1% NAV) with tight stop-losses (30%) until >3 months of stable volume. Pair trade: reduce small-cap European MedTech exposure and rotate into larger-cap, liquid names (buy IHI or DHR) to capture safer medtech beta; reallocate 1–3% NAV over 1–4 weeks. Options: buy 3-month IHI call spreads (1–2% notional) to express asymmetric upside from sector rotation; avoid single-stock options on SciBase unless deep liquidity appears.

Contrarian angles: Consensus focuses on dilution pain and near-term weakness but may underweight the value of ~80 MSEK+ of fresh capital if spent efficiently—if management can deliver a clear commercial rollout within 6–12 months the low base could offer high upside. The market may overprice permanent damage; historical small-cap biotech/device raises saw 6–12 month recoveries when proceeds funded clear go-to-market catalysts. Unintended consequence: heavy insider/anchor selling after listing could create technical squeezes; watch block trades and nominee allocations carefully.

Key Decisions for Investors

• If you can borrow SciBase shares, establish a tactical short (size 0.5–1.0% of portfolio NAV) on or within 5 trading days after trading recommences (~19 Feb 2026), target exit at SEK 0.20–0.25 (subscription-price anchoring) within 1–3 months, stop-loss at +30% above entry.
• If bullish on medtech exposure but risk averse, sell 1–3% of small-cap European MedTech holdings and buy IHI (iShares U.S. Medical Devices ETF) or DHR (Danaher, ticker DHR) over 1–4 weeks to reduce single-stock dilution risk and capture sector upside.
• If you have conviction in a post-dilution recovery and can accept high volatility, establish a limited long in SciBase <=0.5% NAV only if post-listing VWAP over 5 days is <= SEK 0.20; target 100–200% upside over 12 months, cut if no commercial milestones in 6 months.
• Use options on IHI: buy 3-month call spreads 2–5% OTM (size 1–2% notional) as a directional play on sector rotation into larger-cap medtech while avoiding illiquid SciBase single-stock options.
• Monitor three triggers before increasing exposure: (1) 30-day post-listing daily volume >1.0% float, (2) management publishes a 12–18 month cash runway or milestone-driven use of proceeds within 60 days, (3) no material negative ISP/FDI Act notices affecting >10% share acquisitions.